<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04006808</url>
  </required_header>
  <id_info>
    <org_study_id>200075</org_study_id>
    <secondary_id>2019-000607-33</secondary_id>
    <nct_id>NCT04006808</nct_id>
  </id_info>
  <brief_title>A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant</brief_title>
  <official_title>A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2&#xD;
      doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in&#xD;
      immunocompromised paediatric renal transplant recipients aged 1-17 years&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects from the interventional groups, with solicited local adverse events (AEs)</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>Assessed solicited local AEs are pain, redness and swelling at the injection site. Pain includes tenderness.&#xD;
Note: GSK diary cards for collecting solicited local and general AEs/symptoms is different for subjects &lt; 6 years and ≥ 6 years. Hence the age category of 1-11 years is further split to 1-5 years and 6-11 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the interventional groups, with solicited general AEs</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>Assessed solicited general AEs among Infants/Toddlers/Children &lt; 6 years are:&#xD;
Drowsiness&#xD;
Fever*&#xD;
Irritability/Fussiness&#xD;
Loss of appetite&#xD;
Gastrointestinal (GI) symptoms**&#xD;
Assessed solicited general AEs among Children ≥ 6 years are:&#xD;
Fatigue&#xD;
Fever*&#xD;
GI symptoms**&#xD;
Headache&#xD;
Myalgia&#xD;
Shivering (chills)&#xD;
Fever is defined as temperature ≥ 38.0°C/100.4°F **GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain Note: GSK diary cards for collecting solicited local and general AEs/symptoms is different for subjects &lt; 6 years and ≥ 6 years. Hence the age category of 1-11 years is further split to 1-5 years and 6-11 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the control groups with solicited general symptoms</measure>
    <time_frame>Within 7 days after Visit Day 1</time_frame>
    <description>Assessed solicited general symptoms among Infants/Toddlers/Children &lt; 6 years are:&#xD;
Drowsiness&#xD;
Fever*&#xD;
Irritability/Fussiness&#xD;
Loss of appetite&#xD;
GI symptoms**&#xD;
Assessed solicited general symptoms among Children ≥ 6 years are:&#xD;
Fatigue&#xD;
Fever*&#xD;
GI symptoms**&#xD;
Headache&#xD;
Myalgia&#xD;
Shivering (chills)&#xD;
Fever is defined as temperature ≥ 38.0°C/100.4°F **GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain As subjects from the control group are not vaccinated, they will not complete the diary card for local solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the control groups with solicited general symptoms</measure>
    <time_frame>Within 7 days after Visit Month 1</time_frame>
    <description>Assessed solicited general symptoms among Infants/Toddlers/Children &lt; 6 years are:&#xD;
Drowsiness&#xD;
Fever*&#xD;
Irritability/Fussiness&#xD;
Loss of appetite&#xD;
GI symptoms**&#xD;
Assessed solicited general symptoms among Children ≥ 6 years are:&#xD;
Fatigue&#xD;
Fever*&#xD;
GI symptoms**&#xD;
Headache&#xD;
Myalgia&#xD;
Shivering (chills)&#xD;
Fever is defined as temperature ≥ 38.0°C/100.4°F **GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the interventional groups with unsolicited AEs after each vaccination</measure>
    <time_frame>Within 30 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the control groups with unsolicited symptoms</measure>
    <time_frame>Within 30 days after Visit Day 1</time_frame>
    <description>An unsolicited symptom is any symptom reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the control groups with unsolicited symptoms</measure>
    <time_frame>Within 30 days after Visit Month 1</time_frame>
    <description>An unsolicited symptom is any symptom reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with serious adverse events (SAEs), potential immune mediated diseases (pIMDs) and biopsy confirmed renal allograft rejection.</measure>
    <time_frame>From Visit Day 1 up to Visit Month 2</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.&#xD;
pIMDs are sub sets of Adverse events of special interest (AESIs) that include autoimmune disease and other inflammatory and/neurological disorders of interest, which may or may not have autoimmune aetiology.&#xD;
The renal allograft rejections are biopsy confirmed pathophysiological changes indicative of rejection. The rejection is graded for severity and extent of histologic inflammation and injury. The reporting period for any renal allograft rejection is from Visit Day 1 to the study end (month 2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the interventional groups with seizures</measure>
    <time_frame>Within 30 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>All seizures occurring within 30 days following study vaccination are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the non-interventional groups with seizures</measure>
    <time_frame>Within 30 days after Visit Day 1</time_frame>
    <description>All seizures occurring within 30 days after visit day 1 are reported, for the control groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the non-interventional groups with seizures</measure>
    <time_frame>Within 30 days after Visit Month 1</time_frame>
    <description>All seizures occurring within 30 days of visit month 1 are reported, for the control groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the interventional groups with generalized convulsive seizures</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>Generalized convulsive seizures are classified as follows:&#xD;
Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations&#xD;
Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above&#xD;
Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the non-interventional groups with generalized convulsive seizures</measure>
    <time_frame>Within 7 days after Visit Day 1</time_frame>
    <description>Generalized convulsive seizures are classified as follows:&#xD;
Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations&#xD;
Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above&#xD;
Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects from the non-interventional groups with generalized convulsive seizures</measure>
    <time_frame>Within 7 days after Visit Month 1</time_frame>
    <description>Generalized convulsive seizures are classified as follows:&#xD;
Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations&#xD;
Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above&#xD;
Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with Anti-gE antibody concentrations in terms of Geometric Mean Concentrations (GMCs)</measure>
    <time_frame>At Month 2 (one-month post-dose 2)</time_frame>
    <description>The geometric mean concentration (GMC) calculations are performed by taking the anti log of the mean of the log concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for GMC calculation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with SAEs, pIMDs and biopsy confirmed renal allograft rejections from day 1 to month 13</measure>
    <time_frame>From Visit Day 1 up to Visit Month 13</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity pIMDs are sub sets of Adverse events of special interest (AESIs) that include autoimmune disease and other inflammatory and/neurological disorders of interest, which may or may not have autoimmune aetiology.&#xD;
The renal allograft rejections are biopsy confirmed pathophysiological changes indicative of rejection. The rejection is graded for severity and extent of histologic inflammation and injury.&#xD;
This outcome measure is analysed during epoch 002 (day 1 to month 2) and during epoch 003 (month 2- month 13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Herpes Zoster cases</measure>
    <time_frame>From Visit Day 1 until Visit Month 13</time_frame>
    <description>HZ may present classically with a unilateral, dermatomal rash that is associated with pain, pruritus, allodynia or other altered sensation. In this population, disseminated HZ may occur and present with a generalized rash with systemic symptoms such as fever. All children enrolled in the trial have a history of primary VZV infection or vaccination and in the presence of immunosuppression, disseminated HZ cannot be distinguished clinically from varicella This outcome measure is analysed during epoch 002 (day 1 to month 2) and during epoch 003 (month 2- month 13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the interventional pooled age group with solicited local AEs</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years.&#xD;
The assessed local AEs solicited are:&#xD;
Pain&#xD;
Redness&#xD;
Swelling Note: Pain includes tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the interventional pooled age group with solicited general AEs</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years.&#xD;
The assessed solicited general AEs among Infants/Toddlers/Children &lt; 6 years are:&#xD;
Drowsiness&#xD;
Fever*&#xD;
Irritability/Fussiness&#xD;
Loss of appetite&#xD;
Gastrointestinal (GI) symptoms**&#xD;
The assessed solicited general AEs among Children ≥ 6 years are:&#xD;
Fatigue&#xD;
Fever*&#xD;
GI symptoms**&#xD;
Headache&#xD;
Myalgia&#xD;
Shivering (chills)&#xD;
Fever is defined as temperature ≥ 38.0°C/100.4°F **GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with solicited general symptoms</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years.&#xD;
The assessed solicited general symptoms among Infants/Toddlers/Children &lt; 6 years are:&#xD;
Drowsiness&#xD;
Fever*&#xD;
Irritability/Fussiness&#xD;
Loss of appetite&#xD;
GI symptoms**&#xD;
The assessed solicited general symptoms among Children ≥ 6 years are:&#xD;
Fatigue&#xD;
Fever*&#xD;
GI symptoms**&#xD;
Headache&#xD;
Myalgia&#xD;
Shivering (chills)&#xD;
Fever is defined as temperature ≥ 38.0°C/100.4°F **GI symptoms include nausea, vomiting, diarrhoea, and/or abdominal pain As subjects from the control group are not vaccinated, they will not complete the diary card for local solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the interventional pooled age group with unsolicited AEs after each vaccination</measure>
    <time_frame>Within 30 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years. An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with unsolicited symptoms</measure>
    <time_frame>Within 30 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years. An unsolicited symptom is any symptom reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with unsolicited symptoms</measure>
    <time_frame>Within 30 days after Visit Month 1</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years. An unsolicited symptom is any symptom reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the pooled age groups with any SAEs, pIMDs and biopsy confirmed renal allograft rejections</measure>
    <time_frame>From Visit Day 1 until Visit Month 2</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity pIMDs are sub sets of Adverse events of special interest (AESIs) that include autoimmune disease and other inflammatory and/neurological disorders of interest, which may or may not have autoimmune aetiology.&#xD;
The renal allograft rejections are biopsy confirmed pathophysiological changes indicative of rejection. The rejection is graded for severity and extent of histologic inflammation and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the pooled age groups with any SAEs, pIMDs and biopsy confirmed renal allograft rejections</measure>
    <time_frame>From Visit Day 1 until Visit Month 13</time_frame>
    <description>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity pIMDs are sub sets of Adverse events of special interest (AESIs) that include autoimmune disease and other inflammatory and/neurological disorders of interest, which may or may not have autoimmune aetiology.&#xD;
The renal allograft rejections are biopsy confirmed pathophysiological changes indicative of rejection. The rejection is graded for severity and extent of histologic inflammation and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the pooled age groups with HZ</measure>
    <time_frame>From Visit Day 1 until Visit Month 13</time_frame>
    <description>HZ may present classically with a unilateral, dermatomal rash that is associated with pain, pruritus, allodynia or other altered sensation. In this population, disseminated HZ may occur and present with a generalized rash with systemic symptoms such as fever. All children enrolled in the trial have a history of primary VZV infection or vaccination and in the presence of immunosuppression, disseminated HZ cannot be distinguished clinically from varicella.&#xD;
This outcome measure is analysed during epoch 002 (day 1 to month 2) and during epoch 003 (month 2- month 13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the interventional pooled age group with seizures</measure>
    <time_frame>Within 30 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years. All seizures occurring within 30 days following study vaccination are reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with seizures</measure>
    <time_frame>Within 30 days after Visit Day 1</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years. All seizures occurring with 30 days after visit day 1 are reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with seizures</measure>
    <time_frame>Within 30 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years. All seizures occurring with 30 days after visit month 1 are reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the interventional pooled age group with generalized convulsive seizures</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years.&#xD;
Generalized convulsive seizures are classified as follows:&#xD;
Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations&#xD;
Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above&#xD;
Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with generalized convulsive seizures</measure>
    <time_frame>Within 7 days after each vaccination (vaccines administered on day 1 and month 1)</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years.&#xD;
Generalized convulsive seizures are classified as follows:&#xD;
Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations&#xD;
Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above&#xD;
Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects from the non-interventional pooled age group with generalized convulsive seizures</measure>
    <time_frame>Within 7 days after Visit Month 1</time_frame>
    <description>The pooled age group includes all subjects aged 1-17 years.&#xD;
Generalized convulsive seizures are classified as follows:&#xD;
Level 1 of diagnostic certainty: witnessed sudden loss of consciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 2 of diagnostic certainty: history of unconsciousness AND generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations&#xD;
Level 3 of diagnostic certainty: history of unconsciousness AND other generalized motor manifestations&#xD;
Level 4 of diagnostic certainty: reported generalized convulsive seizure with insufficient evidence to meet the case definitions for Level 1, 2 or 3 of diagnostic certainty above&#xD;
Level 5 of diagnostic certainty: Not a case of generalized convulsive seizure Only levels 1 to 3 of generalized convulsive seizures will comprise the analysis for this outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rate (VRR) for Anti-glycoprotein (Anti-gE) antibody concentrations</measure>
    <time_frame>At Month 2 and Month 13</time_frame>
    <description>The Vaccine Response Rate for anti-gE antibodies is defined as the percentage of subjects who have at least:&#xD;
a 4-fold increase in the post-dose 2 anti-gE Ab concentration as compared to the pre-vaccination anti-gE Ab concentration, for subjects who are seropositive at baseline, or,&#xD;
a 4-fold increase in the post-dose 2 anti-gE Ab concentration as compared to the anti-gE Ab cut-off value for seropositivity, for subjects who are seronegative at baseline.&#xD;
This outcome measure is analysed during epoch 002 (day 1 to month 2) and during epoch 003 (month 2- month 13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median fold increase of anti-gE antibody concentrations</measure>
    <time_frame>At Month 2 and Month 13</time_frame>
    <description>Median fold increase in antibody concentration with 95% Confidence Interval is tabulated for the interventional groups by age strata (1-11 years and 12-17 years) This outcome measure is analysed during epoch 002 (day 1 to month 2) and during epoch 003 (month 2- month 13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with anti-gE antibody concentrations in terms of GMCs</measure>
    <time_frame>At Day 1 (pre-vaccination) and Month 13</time_frame>
    <description>GMC calculations are performed by taking the anti log of the mean of the log concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for GMC calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects in the interventional pooled age group, with Anti-gE antibody concentrations in terms of GMCs</measure>
    <time_frame>At Day 1, Month 2 and Month 13</time_frame>
    <description>GMC calculations are performed by taking the anti log of the mean of the log concentration transformations. Antibody concentrations below the cut-off of the assay will be given an arbitrary value equal to half the cut-off for GMC calculation.&#xD;
Median fold increase in antibody concentration with 95% Confidence Interval is to be tabulated for the interventional groups by pooled age category (1-17 years).&#xD;
This outcome measure is analysed during epoch 002 (day 1 to month 2) and during epoch 003 (month 2- month 13)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>PED-HZ/su 12-17 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 12-17 Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PED-HZ/su 1-11 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su).&#xD;
Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 1-11 Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PED-HZ/su</intervention_name>
    <description>GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.</description>
    <arm_group_label>PED-HZ/su 1-11 Group</arm_group_label>
    <arm_group_label>PED-HZ/su 12-17 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s) who, in the opinion&#xD;
             of the investigator, can and will comply, with the requirements of the protocol&#xD;
&#xD;
          -  Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s)&#xD;
             of the subject prior to performance of any study specific procedure.&#xD;
&#xD;
          -  Written informed assent obtained from the subjects when applicable according to local&#xD;
             requirements.&#xD;
&#xD;
          -  A male or female between, and including, 1 and 17 years of age at the time of&#xD;
             randomisation (Visit Day 1)&#xD;
&#xD;
          -  Body weight ≥ 6 kg/13.23 pounds.&#xD;
&#xD;
          -  A subject is eligible if they meet at least one of the following criteria:&#xD;
&#xD;
               -  Documented previous VZV vaccination OR&#xD;
&#xD;
               -  Medically verified varicella (with source documentation) OR&#xD;
&#xD;
               -  Seropositive for VZV prior to transplantation.&#xD;
&#xD;
          -  Subjects with renal transplant more than six months (180 days) prior randomization&#xD;
             (Visit Day 1)&#xD;
&#xD;
          -  Subject who has received an ABO compatible allogeneic renal transplant (allograft).&#xD;
&#xD;
          -  Subject with stable renal function with stability defined as &lt;20% variability between&#xD;
             the last two creatinine measurements or based on investigator opinion after review of&#xD;
             multiple creatinine measurements.&#xD;
&#xD;
          -  Subject receiving maintenance immunosuppressive therapy for the prevention of&#xD;
             allograft rejection for a minimum of one month (30 days) prior to randomization (Visit&#xD;
             Day 1).&#xD;
&#xD;
          -  Female subjects of childbearing potential may be enrolled in the study, if the subject&#xD;
&#xD;
               -  has practiced adequate contraception for 30 days prior to Visit Day 1 and has&#xD;
                  agreed to continue adequate contraception during the entire treatment period and&#xD;
                  for 2 months after completion of the vaccination series&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical conditions&#xD;
&#xD;
          -  Any primary kidney disease with a high incidence of recurrent primary kidney disease&#xD;
             within the allograft&#xD;
&#xD;
          -  Evidence of recurrent primary kidney disease within the current allograft&#xD;
&#xD;
          -  Previous allograft loss secondary to recurrent primary kidney disease&#xD;
&#xD;
          -  History of more than one organ transplanted (that is, kidney-liver, simultaneous&#xD;
             double kidney or kidney-other organ(s) transplanted).&#xD;
&#xD;
          -  Subjects with an episode of acute allograft rejection over the six months (180 days)&#xD;
             prior to enrolment&#xD;
&#xD;
          -  Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency&#xD;
             (cRF) score that is unknown at the time of transplant&#xD;
&#xD;
          -  VZV serostatus unknown prior to transplant&#xD;
&#xD;
          -  Subjects with advanced chronic kidney disease&#xD;
&#xD;
          -  Evidence of significant proteinuria (≥ 200 g/mol creatinine) believed to be of renal&#xD;
             origin (an example of non-renal origin is proteinuria from mucus in a reconstructed&#xD;
             bladder)&#xD;
&#xD;
          -  Subjects without multiple dialysis options in the event acute or chronic dialysis&#xD;
             needed.&#xD;
&#xD;
          -  History of unstable or progressive neurological disorder.&#xD;
&#xD;
          -  Subjects ≤ 5 years of age with a history of one or more simple or complex febrile&#xD;
             seizures&#xD;
&#xD;
          -  Subjects &gt; 5 years with history of one or more complex febrile seizures&#xD;
&#xD;
          -  Occurrence of a varicella or HZ episode by clinical history within the 6 months (180&#xD;
             days) preceding Visit Day 1&#xD;
&#xD;
          -  Any autoimmune disease, with the following exceptions which do not constitute an&#xD;
             exclusion criterion:&#xD;
&#xD;
               -  IgA nephropathy&#xD;
&#xD;
               -  Rapidly progressive glomerulonephritis&#xD;
&#xD;
               -  Membranous glomerulonephritis&#xD;
&#xD;
               -  Idiopathic Type I membranoproliferative glomerulonephritis&#xD;
&#xD;
               -  Diabetes mellitus (type 1 and 2) with diabetic nephropathy&#xD;
&#xD;
          -  Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency&#xD;
             disease&#xD;
&#xD;
          -  Any other clinical condition that, in the opinion of the investigator, might pose&#xD;
             additional risk to the subject due to participation in the study&#xD;
&#xD;
          -  History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the vaccine&#xD;
&#xD;
          -  Any condition which, in the judgement of the investigator would make intramuscular&#xD;
             injection unsafe.&#xD;
&#xD;
          -  Atypical Haemolytic Uraemic Syndrome.&#xD;
&#xD;
        Prior/Concomitant therapy&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study vaccine&#xD;
             during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned&#xD;
             use during the study period.&#xD;
&#xD;
          -  Subject in receipt of treatment for rejection during the six months (180 days) prior&#xD;
             to enrolment.&#xD;
&#xD;
          -  Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day&#xD;
             1 or planned administration during the duration of the study.&#xD;
&#xD;
          -  Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned&#xD;
             administration during the duration of the study.&#xD;
&#xD;
          -  Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned&#xD;
             administration of immunoglobulins during the duration of the study.&#xD;
&#xD;
          -  Administration or planned administration of a vaccine within 30 days prior to Visit&#xD;
             Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza&#xD;
             vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days&#xD;
             prior to or 14 days after Visit Month 1.&#xD;
&#xD;
          -  Previous vaccination against HZ&#xD;
&#xD;
          -  Varicella vaccination within the 6 months (180 days) preceding Visit Day 1&#xD;
&#xD;
          -  Planned administration during the study of an HZ or varicella vaccine (including an&#xD;
             investigational or non-registered vaccine) other than the study vaccine&#xD;
&#xD;
        Prior/Concurrent clinical study experience&#xD;
&#xD;
        • Concurrent or planned participation in another clinical study, at any time during the&#xD;
        study period, in which the subject has been or will be exposed to an investigational or a&#xD;
        non-investigational product&#xD;
&#xD;
          -  available locally through compassionate use programs,&#xD;
&#xD;
          -  submitted for and pending local/country registration,&#xD;
&#xD;
          -  approved and registered for use in other countries with well-documented Summary of&#xD;
             Product Characteristics or Prescribing Information&#xD;
&#xD;
          -  The name of the active component(s) of these immunosuppressants must be provided in&#xD;
             the concomitant medication listing&#xD;
&#xD;
        Other exclusions&#xD;
&#xD;
          -  Child in care&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions (if of childbearing potential) between one month (30 days) prior to Visit&#xD;
             Day 1 through two months (60 days) after Visit Month 1.&#xD;
&#xD;
          -  Evidence or high suspicion, in the opinion of the investigator, of non-compliance or&#xD;
             non-adherence to use of induction and/or maintenance immunosuppressive therapies.&#xD;
&#xD;
          -  Failure to fully complete the 7-day pre-vaccination diary card distributed at the&#xD;
             Pre-vaccination visit&#xD;
&#xD;
               -  Completion must cover the 7 days immediately prior to randomisation (Visit Day&#xD;
                  1).&#xD;
&#xD;
               -  Completion is defined as a minimum of 6 days completed.&#xD;
&#xD;
               -  Subjects with less than 6 days completed may be offered a new date for Visit Day&#xD;
                  1 and the opportunity to comply with the completion of the 7-day pre-vaccination&#xD;
                  diary card prior to the new planned Visit Day 1.&#xD;
&#xD;
          -  Any study personnel or their immediate dependants, family, or household member.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jérôme Harambat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Annie Manucci-Lahoche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Florentine Garaix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier cedex</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Fila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gwénaëlle Roussey-Kesler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Olivia Gillion-Boyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Julien Hogan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stéphane Decramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Isabella Guzzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto Magnasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Montini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roberta Camilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luisa Murer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baracaldo/Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mireia Aguirre Meñica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Martínez Gómez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Esplugues De Llobregat. Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Álvaro Domingo Madrid Aris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Barraca Núñez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Teresa del Rosal Rabes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco De la Cerda Ojeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mordi Muorah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shivaram Hegde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ben Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Marks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohan Shenoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Jin Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

